Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial
John W. Eikelboom
, Sanjit S. Jolly
, Emilie P. Belley-Cote
, Richard P. Whitlock
, Sumathy Rangarajan
, Lizhen Xu
, Laura Heenan
, Shrikant I. Bangdiwala
, Maria Luz Diaz
, Rafael Diaz
, Afzalhussein Yusufali
, Sanjib Kumar Sharma
, Wadea M. Tarhuni
, Mohamed Hassany
, Alvaro Avezum
, William Harper
, Sean Wasserman
, Aysha Almas
, Oxana Drapkina
, Camilo Felix
Renato D. Lopes, Otavio Berwanger, Patricio Lopez-Jaramillo, Sonia S. Anand, Jackie Bosch, Shurjeel Choudhri, Michael E. Farkouh, Mark Loeb, Salim Yusuf
Profundice en los temas de investigación de 'Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial'. En conjunto forman una huella única.
Keyphrases
Pharmacology, Toxicology and Pharmaceutical Science